What is Inscripta?
Inscripta is at the forefront of developing a revolutionary benchtop platform designed for scalable digital genome engineering. Their comprehensive CRISPR-based system integrates an instrument, specialized consumables, sophisticated software, and advanced assays. This fully automated workflow enables massively parallel, trackable editing of single cells at an unprecedented scale. Established in 2015 and headquartered in Boulder, Colorado, Inscripta is poised to transform genetic research and development through its advanced technological capabilities.
How much funding has Inscripta raised?
Inscripta has raised a total of $417.5M across 6 funding rounds:
Series A
$6M
Series B
$23M
Series C
$55.5M
Series D
$125M
Unspecified
$58M
Series E
$150M
Series A (2016): $6M, investors not publicly disclosed
Series B (2017): $23M led by Venrock Healthcare Partners, Paladin Capital Group, Foresite Capital, NanoDimension, and Spruce/MLS
Series C (2018): $55.5M supported by Mérieux Développement, Venrock, and Paladin Capital Group
Series D (2019): $125M featuring Oak HC/FT, Mérieux Développement, Venrock, NanoDimension, Foresite, MLS Capital, Paladin Capital Group, and JS Capital Management LLC
Unspecified (2020): $58M, investors not publicly disclosed
Series E (2021): $150M with participation from T. Rowe Price and Fidelity Management Corporation
Key Investors in Inscripta
T. Rowe Price
T. Rowe Price is a global investment management firm founded in 1937, known for managing equity and fixed income mutual funds for individuals and institutional investors. Their involvement suggests a focus on established growth potential and long-term value.
Oak HC/FT
Oak HC/FT is a venture growth-equity fund established in 2014, specializing in healthcare information & services and financial services technology. Their investment indicates a strategic interest in Inscripta's impact on healthcare and technology sectors.
Venrock
Venrock, a venture capital firm founded in 1969, has a long history of backing innovative technology and healthcare companies. Their participation highlights Inscripta's alignment with Venrock's focus on disruptive ventures and entrepreneurial support.
What's next for Inscripta?
The recent major strategic investment in Inscripta signals a strong validation of its technology and market strategy. This capital infusion is expected to accelerate the company's expansion, enhance its product development pipeline, and broaden its market reach. As Inscripta continues to scale its operations, it is well-positioned to solidify its leadership in the rapidly evolving field of genome engineering, driving innovation in biotechnology and life sciences.
See full Inscripta company page
